A61K 40/4277
Fusion proteins originating from gene translocation in cancer cells
Official title: {Fusion proteins originating from gene translocation in cancer cells}
A61K40/4277 (Fusion proteins originating from gene translocation in cancer cells) appears on 8 US grants and 19 published applications in this corpus.
Search patents in A61K- Granted patents
- 8
- Published applications
- 19
- Assignees
- 12
- Inventors
- 29
- Latest grant
- 28 Oct 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 1 |
| 2006 | 0 | 1 |
| 2007 | 0 | 2 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 1 | 0 |
| 2011 | 1 | 1 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 5 |
| 2019 | 0 | 2 |
| 2020 | 0 | 0 |
| 2021 | 0 | 2 |
| 2022 | 1 | 5 |
| 2023 | 0 | 0 |
| 2024 | 1 | 0 |
| 2025 | 3 | 0 |
By publication year. Applications have been published since 2001.
Subgroups
Granted patents
Recent patents
- Complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for treatment of glioblastoma28 Oct 2025US 12,453,762 B2Amal Therapeutics SA
- Fusion comprising a cell penetrating peptide, a multi epitope and a TLR peptide agonist for treatment of cancer11 Feb 2025US 12,220,387 B2Amal Therapeutics SA
- Complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for treatment of colorectal cancer11 Feb 2025US 12,220,450 B2Amal Therapeutics SA
- Complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist31 Dec 2024US 12,178,788 B2Amal Therapeutics SA
- Fusion comprising a cell penetrating peptide, a multi epitope and a TLR peptide agonist for treatment of cancer24 May 2022US 11,338,027 B2Amal Therapeutics SA
- Immunotherapy Targeting Tumor Neoantigenic Peptides22 Dec 2022US 2022/0401539 A1Institut Curie
- Fusion Comprising A Cell Penetrating Peptide, A Multi Epitope And A TLR Peptide Agonist For Treatment Of Cancer29 Sep 2022US 2022/0305101 A1Amal Therapeutics SA
- Novel Complex Comprising A Cell Penetrating Peptide, A Cargo And A TLR Peptide Agonist For Treatment Of Glioblastoma9 Jun 2022US 2022/0175933 A1Amal Therapeutics SA
- Novel Complex Comprising A Cell Penetrating Peptide, A Cargo And A TLR Peptide Agonist10 Feb 2022US 2022/0040314 A1Amal Therapeutics SA
- Complex Comprising A Cell Penetrating Peptide, A Cargo And A TLR Peptide Agonist For Treatment Of Colorectal Cancer3 Feb 2022US 2022/0031850 A1Amal Therapeutics SA
Most cited
By later US patents
- Peptides containing a fusion joint of a chimeric protein encoded by DNA spanning a tumor-associated chromosomal translocation and their use as immunogens12US 5,997,869 AThe United States of America as represented by the Department of Health and Human Services · 1999
- Fusion comprising a cell penetrating peptide, a multi epitope and a TLR peptide agonist for treatment of cancer5US 11,338,027 B2Amal Therapeutics SA · 2022
- Methods and compositions for expanding T regulatory cells3US 7,745,215 B2University of Louisville Research Foundation, Inc. · 2010